Clinical trials in Biberach An Der Riss

The ongoing trials in Biberach An Der Riss are centered on assessing relative bioavailability of investigational tablets in healthy volunteers. Researchers compare how different formulations deliver the active compound under controlled conditions.

• Comparison of two tablet formulations of a dopamine agonist
• Evaluation of fasted versus fed administration for the same tablet
• Impact of co‑administrated esomeprazole on drug exposure
• Measurement of plasma concentrations across study arms

Findings will support optimal dosing strategies and inform future product development.

Several studies investigate how concomitant medicines alter the pharmacokinetic profile of a primary agent in healthy men. The goal is to identify potential interactions that could affect efficacy or safety.

• Vicadrostat and empagliflozin administered separately and together
• Bosentan’s influence on nerandomilast plasma levels
• Assessment of combined versus individual dosing regimens
• Documentation of any adverse interaction signals

Results will guide clinicians on safe co‑prescribing practices.

A subset of trials examines how meals and acid‑reducing agents modify drug absorption, using fasted and fed states as variables. Understanding these effects helps optimize administration recommendations.

• Comparison of tablet absorption under fasting conditions
• Evaluation of the same tablet after a standard high‑fat meal
• Influence of esomeprazole on gastric pH and drug uptake
• Quantification of changes in blood concentration metrics

Data will be used to label instructions regarding food and antacid use.

Biberach An Der Riss hosts a focused program that enrolls healthy volunteers to generate early pharmacokinetic and safety data for new chemical entities. The objective is to build a robust dataset before patient trials commence.

• Recruitment of screened volunteers for controlled dosing
• Intensive blood sampling for pharmacokinetic profiling
• Monitoring of safety endpoints throughout the study

This approach accelerates decision‑making for downstream clinical development.